Accelerate Diagnostics reports Q1 2018 financial results
May 10, 2018
Accelerate Diagnostics, Inc. today announced financial results for the quarter ending March 31, 2018. The company generated revenue of $801,000, up 51% from the prior year, and reported signed agreements for 345 instruments. Contracts for customer evaluations total 256 instruments while revenue generating placements grew to 89 across the U.S. and European regions.
See the company’s press release for additional details.
- Studies Confirm Rapid Phenotypic Susceptibility Results Enable Earlier Antimicrobial Intervention and Better Patient Outcomes
Oct 03, 2019
- Clinical Endpoints Achieved Across Mayo Clinic/UCLA, University of Iowa, and UAMS Studies
Sep 18, 2019
- Accelerate Diagnostics Expands Antimicrobials in New CE-Marked Accelerate PhenoTest™ BC kit
Aug 02, 2019